Evox Therapeutics

Evox Therapeutics is a biotechnology company developing exosome therapeutics using exosomes, cell-derived vesicles, to deliver small and large molecule therapeutics. The company is headquartered in Oxford, Oxfordshire, United Kingdom and was founded in 2016 by Per Lundin.



The company has a proprietary technology to modify exosomes to target specific organs such as the brain and central nervous system.Evox Therapeutics has built an intellectual property portfolio encompassing key aspects of extracellular vesicle-based nucleic acid and protein delivery technology. 

Funding

Series A

On May 16, 2016 Evox Therapeutics completed their series A funding round with £10 in funding from Oxford Sciences Innovation. 

Series B

On September 2, 2018 Evox Therapeutics completed their series B funding round with £35 in funding from Redmile Group (lead investor), Panacea Venture, Oxford University Innovation, Oxford Sciences Innovation, GV, Cowen Healthcare Investments, and Borealis Ventures. 

Grant - Duchenne UK

On November 13, 2018 Evox therapeutics was awarded in grant from Duchenne UK worth £655 thousand. 

Grant - Innovative UK

On March 22, 2019 Evox Therapeutics was awarded a grant from Innovative UK worth £1.5 million.